Search results
Results From The WOW.Com Content Network
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. [5] It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. [8]
In 1961, the company changed its name to Automatic Data Processing, Inc. (ADP), and began using punched card machines, check printing machines, and mainframe computers. ADP went public in 1961 with 300 clients, 125 employees, and revenues of approximately US$400,000. [3] The company established a subsidiary in the United Kingdom in 1965.
Antiplatelet drug. An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation. They are effective in the arterial circulation where classical Vitamin K antagonist ...
It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB 1 receptor with a binding affinity (K i) of 0.33 nM and an EC 50 of 14.7 nM. [3] ADB-BUTINACA [ edit ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
May 13, 2024 at 4:22 PM. Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients. Pfizer Inc (NYSE: PFE) is looking to build on the success of its COVID-19 vaccine rollout by ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. [44] [45] It is authorized for use ...
Adenosine diphosphate ( ADP) receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke. These drugs antagonize the P2Y 12 platelet receptors and therefore prevent the binding of ...